|Day Low/High||92.17 / 94.42|
|52 Wk Low/High||47.71 / 97.80|
Here's how to trade some of the most active names on the market today.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Questcor...
Questcor Pharmaceuticals has been a controversial stock for years, as short selling research firm Citron Research raised concerns about the company's Acthar gel, which is marketed for multiple sclerosis and other autoimmune and inflammatory disorders.
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Questcor Pharmaceuticals Inc.
Irish specialty pharma plans to take California target's Acthar gel international.
Investors on StockTwits.com believe Monday's $5.6 billion merger between Mallinckrodt and Questcor Pharmaceuticals will spur more acquisitions and support valuations in the biotech sector. Here are some of the other companies singled out as takeout targets.
Levi & Korsinsky is investigating the Board of Directors of Questcor Pharmaceuticals Inc.
Whenever you see a deal like Mallinckrodt buying Questcor, you have to ask: Is this a case of smart seller, dumb buyer? I've done zero work on Questcor, but over the past few years I've talked to a few very serious short-sellers who have. When I saw the news this morning, the first thing that crossed my mind: Mattel buying The Learning Company....Hewlett Packard buying Autonomy...Medtronic buying Arterial Vascular Engineering. All three of the targets were the focus of short-sellers, and all three famously blew up, or otherwise caused havoc, once inside the new parent -- for the very reason the short-sellers had been short. Mattel was perhaps the most wounded, and almost taken down by what it found once it owned The Learning Company. No idea if that will happen here, but a quick peek at Mallinckrodt's history sure is a twisted tale....
Shares of Questcor surge before market open on Monday after it announces a $5.6 billion deal to be acquired by Mallinckrodt.
U.S. stock futures are pointing to a lower open on Wall Street Monday, extending Friday's selloff.
Trade-Ideas LLC identified Questcor Pharmaceuticals (QCOR) as a pre-market leader candidate
Questcor Pharmaceuticals was a winner within the drugs industry, rising $3.04 (4.4%) to $72.17 on average volume
Investors in Questcor Pharmaceuticals Inc saw new options become available today, for the May 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the QCOR options chain for the new May 23rd contracts and identified one put and one call contract of particular interest.
Cramer says he's disappointed by Volaris, missed on Endocyte but likes GNC Holdings and Chicago Mercantile Exchange.
Cramer says the only thing shocking about Michael Lewis's new book on high-frequency trading is that people find it shocking at all.
Questcor Pharmaceuticals was a winner within the health care sector, rising $0.75 (1.2%) to $64.14 on light volume
Investors in Questcor Pharmaceuticals Inc saw new options become available today, for the May 2nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the QCOR options chain for the new May 2nd contracts and identified one put and one call contract of particular interest.
Cramer would rather buy Talisman Energy than sell it and he feels good about Drew Industries.
Ukraine is just another in a long list of foreign crises that have the markets operating on emotion instead of logic, Cramer says.
Trade-Ideas LLC identified Questcor Pharmaceuticals (QCOR) as a "dead cat bounce" (down big yesterday but up big today) candidate
Questcor Pharmaceuticals was a leading decliner within the drugs industry, falling $6.74 (-9.1%) to $67.47 on heavy volume
TheStreet highlights 3 stocks pushing the drugs industry lower today.
Questcor Pharmaceuticals could be moving to Ireland in the next year to help it save cash that could be deployed for acquisitions, according to an industry analyst.
Trade-Ideas LLC identified Questcor Pharmaceuticals (QCOR) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Companies in the Barrow All-Cap Core Fund are merger targets four times more than the market at large because the fund's managers take a private equity approach to stock-picking.
Investors in Questcor Pharmaceuticals Inc saw new options begin trading today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the QCOR options chain for the new April 4th contracts and identified one put and one call contract of particular interest.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.